Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.

Chiaki Suzuki Naomi KiyotaYoshinori ImamuraHideaki GotoHirotaka SutoNaoko ChayaharaMasanori ToyodaYasuhiro ItoAkihiro MiyaAkira MiyauchiNaoki Otsuki Ken-Ichi NibuHironobu Minami

Published in: Head & neck (2019)

Patients with RR-DTC with a high tumor burden and tumor-related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.

Keyphrases

prognostic factors
risk factors
physical activity
sleep quality
drug induced